Augme Technologies Patent Portfolio GROWS and 4 More Fresh Equity Insights
Watson Pharmaceuticals Inc. (NYSE:WPI): A generic form of Adderall XR and a generic version from Actavis, currently being acquired by Watson Pharmaceuticals, have been approved by the FDA. This news supports Goldman’s above consensus earnings estimates for the pharmaceutical company, and Goldman predicts a small impact to Teva (NASDAQ:TEVA) and Impax (NASDAQ:IPXL).
Augme Technologies Inc (OTC:AUGT) has announced that U.S. Patent No. 8,219,642 entitled “System and Method for Adding Targeted Content in a Web Page” has been issued by the United States Patent and Trademark Office. The company also states that his has 80 patent applications currently pending, which includes over 50 applications submitted within the last six months via the successful implementation of ipCapital Group’s invention process. The intellectual property portfolio belonging to Augme has reached 13 issued patents.
Shire plc (NASDAQ:SHPGY) estimates have been reduced by Piper Jaffray after the FDA approved generic Adderall XR as a result of heightened competition. According to the firm, Shire is still attractive because of its numerous top-line drivers which should push double-digit growth and deep pipeline. The firm gives shares an Overweight rating.
Baker Hughes Incorporated (NYSE:BHI) has had its earnings estimates and price targets on the Oil service companies it covers lowered by Citigroup due to the unlikeliness of a growing North American oil services market in 2013-2014, which drives other competitive markets and lower margins. On the other hand, Citi does not predict a steep drilling downturn or drop in share prices similar to 2008-2009 in the future.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.